389629-85-0

Basic information

• Product Name: Propanoic acid, 2,2-dimethyl-, [5-[3-[(4-benzoyl-1-piperazinyl)oxoacetyl]-4-fluoro-1H-indol-7-yl]-2H-tetr azol-2-yl]methyl ester
• CAS NO: 389629-85-0
• Molecular Formula: C28H28FN7O5
• Molecular Weight: 561.573
• Mol File: 389629-85-0.mol

Chemical Properties

• CAS DataBase Reference: Propanoic acid, 2,2-dimethyl-, [5-[3-[(4-benzoyl-1-piperazinyl)oxoacetyl]-4-fluoro-1H-indol-7-yl]-2H-tetr azol-2-yl]methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanoic acid, 2,2-dimethyl-, [5-[3-[(4-benzoyl-1-piperazinyl)oxoacetyl]-4-fluoro-1H-indol-7-yl]-2H-tetr azol-2-yl]methyl ester(389629-85-0)
• EPA Substance Registry System: Propanoic acid, 2,2-dimethyl-, [5-[3-[(4-benzoyl-1-piperazinyl)oxoacetyl]-4-fluoro-1H-indol-7-yl]-2H-tetr azol-2-yl]methyl ester(389629-85-0)

Safety Data

• Hazardous Substances Data: 389629-85-0(Hazardous Substances Data)

Upstream product

• 1416130-68-1 C₁₇H₁₆FN₅O₅ 
• 13754-38-6 N-Benzoylpiperazine 

Relevant articles and documents

Inhibitors of HIV-1 attachment. Part 9: An assessment of oral prodrug approaches to improve the plasma exposure of a tetrazole-containing derivative

7-(2H-Tetrazol-5-yl)-1H-indole 3 was found to be a potent inhibitor of HIV-1 attachment but the compound lacked oral bioavailability in rats. The cause of the low exposure was believed to be poor absorption attributed to the acidic nature of the tetrazole moiety and, in an effort to address this liability, three more lipohilic tetrazole analogs, N-acetoxymethyl 4, N-pivaloyloxymethyl 5, and N-methyl 6, were evaluated as potential oral prodrugs in rats. Prodrug 5 was ineffective in improving the plasma concentration of 3 in vivo but compound 4 provided a 15-fold enhancement of the plasma concentration of 3. Most interestingly, oral dosing of analog 6 afforded a substantial increase in the plasma concentration of the parent in rats when compared to dosing of parent. This represents a novel example of a methyl tetrazole that acts as a prodrug for a free NH tetrazole-containing compound.

Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives

This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with indoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives

The invention comprises substituted indoleoxoacetic piperazine derivatives of general Formula I, compositions thereof and their use as antiviral agents, and particularly for treating HIV infection.